retatrutide triple agonist obesity #elililly #retatrutide #weightloss #obesitycare #glp1 #healthcareinnovation #pharma #biopharma #metabolichealth #pharmanews Weight loss with retatrutide as
Description
Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial
Retatrutide is currently investigational and is not FDA-approved for any indication
Due to the expression of GLP-1 receptors in testicular cells, they can raise testosterone levels and increase sperm motility and metabolism (101)
In addition, it should be noted that the study design did not include a carbohydrate-containing meal or oral administration of l-valine, and the effects of l-valine on postprandial blood glucose were thus not evaluated
Contact your healthcare provider or seek emergency care if symptoms are concerning
Meet with our provider in-office in Hollywood, FL or through secure telehealth
